Nurix Therapeutics (NASDAQ:NRIX) Given Overweight Rating at Stephens
Stephens restated their overweight rating on shares of Nurix Therapeutics (NASDAQ:NRIX – Free Report) in a research report sent to investors on Monday, Benzinga reports. The brokerage currently has a $31.00 price objective on the stock. NRIX has been the subject of several other reports. Jefferies Financial Group initiated coverage on Nurix Therapeutics in a […]
More Stories
Insider Selling: IonQ, Inc. (NYSE:IONQ) CRO Sells $98,184.48 in Stock
IonQ, Inc. (NYSE:IONQ – Get Free Report) CRO Rima Alameddine sold 9,159 shares of the business’s stock in a transaction...
Mathew Kirschner Buys 5,380 Shares of Cohen & Steers Quality Income Realty Fund, Inc. (NYSE:RQI) Stock
Cohen & Steers Quality Income Realty Fund, Inc. (NYSE:RQI – Get Free Report) Portfolio Manager Mathew Kirschner acquired 5,380 shares...
TD Cowen Raises Quanta Services (NYSE:PWR) Price Target to $335.00
Quanta Services (NYSE:PWR – Free Report) had its price objective boosted by TD Cowen from $280.00 to $335.00 in a...
Moody’s (NYSE:MCO) Price Target Raised to $464.00
Moody’s (NYSE:MCO – Free Report) had its price target raised by BMO Capital Markets from $455.00 to $464.00 in a...
Barclays Cuts PagSeguro Digital (NYSE:PAGS) Price Target to $13.00
PagSeguro Digital (NYSE:PAGS – Free Report) had its price objective reduced by Barclays from $16.00 to $13.00 in a report...
Aflac Incorporated (NYSE:AFL) Given Average Rating of “Hold” by Brokerages
Shares of Aflac Incorporated (NYSE:AFL – Get Free Report) have earned a consensus rating of “Hold” from the fifteen analysts...